{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:56:37Z","timestamp":1789872997098,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["D16013"],"award-info":[{"award-number":["D16013"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004387","name":"Ningbo University","doi-asserted-by":"publisher","award":["2026-2"],"award-info":[{"award-number":["2026-2"]}],"id":[{"id":"10.13039\/501100004387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007928","name":"Ningbo Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["2023S048"],"award-info":[{"award-number":["2023S048"]}],"id":[{"id":"10.13039\/501100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bioorg.2026.109877","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:18:23Z","timestamp":1776100703000},"page":"109877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synthesis and evaluation of novel N-arylamide-quinoline derivatives as HDAC isoform-selective inhibitors: in vitro and in vivo anticancer efficacy and pharmacokinetic studies"],"prefix":"10.1016","volume":"176","author":[{"given":"Bingyan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yule","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109877_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","article-title":"Epigenetic therapy for ovarian cancer: promise and progress","volume":"11","author":"Moufarrij","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bioorg.2026.109877_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/abr.abr_142_19","article-title":"Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.bioorg.2026.109877_bb0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.109877_bb0020","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/biom12030367","article-title":"The role of epigenetic modifications in human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2026.109877_bb0025","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.bioorg.2026.109877_bb0030","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/med.21437","article-title":"The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat","volume":"37","author":"Zagni","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.109877_bb0035","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109877_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/17460441.2020.1736032","article-title":"How do we improve histone deacetylase inhibitor drug discovery?","volume":"15","author":"Hamze","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109877_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40264-018-0773-9","article-title":"Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.bioorg.2026.109877_bb0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/13543776.2024.2391289","article-title":"A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013-present)","volume":"34","author":"Banerjee","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.109877_bb0060","doi-asserted-by":"crossref","first-page":"8827","DOI":"10.1021\/acs.jmedchem.0c01676","article-title":"Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy","volume":"64","author":"Adhikari","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0065","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1002\/cncr.34974","article-title":"Recent histone deacetylase inhibitors in cancer therapy","volume":"129","author":"Parveen","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109877_bb0070","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.14698","article-title":"A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma","volume":"178","author":"Batlevi","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bioorg.2026.109877_bb0075","article-title":"Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy","volume":"6","author":"Cao","year":"2022","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109877_bb0080","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1002\/cncr.31761","article-title":"The antitumor effects of entinostat in ovarian cancer require adaptive immunity","volume":"124","author":"Smith","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.109877_bb0085","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.chembiol.2022.03.002","article-title":"Resolving the deceptive isoform and complex selectivity of HDAC1\/2 inhibitors","volume":"29","author":"Payne","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.109877_bb0090","doi-asserted-by":"crossref","first-page":"10080","DOI":"10.1021\/acs.jmedchem.3c00977","article-title":"Discovery of the first irreversible HDAC6 isoform selective inhibitor with potent anti-multiple myeloma activity","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0095","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s11030-019-10013-0","article-title":"Development of classification models for identification of important structural features of isoform-selective histone deacetylase inhibitors (class i)","volume":"24","author":"Neiband","year":"2020","journal-title":"Mol. Divers."},{"key":"10.1016\/j.bioorg.2026.109877_bb0100","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1538-7445.AM2022-5473","article-title":"Isoform-selective HDAC inhibition up-regulates CD26 expression on multiple myeloma cells and augments cytotoxic efficacy by humanized monoclonal antibody","volume":"82","author":"Nishida","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109877_bb0105","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1021\/acs.jmedchem.3c01160","article-title":"Evolution of slow-binding inhibitors targeting histone deacetylase isoforms","volume":"66","author":"Mukherjee","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105407","article-title":"Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities","volume":"117","author":"Zhang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0115","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1021\/acs.jmedchem.3c00614","article-title":"Selective HDAC3 inhibitors with potent in vivo antitumor efficacy against triple-negative breast cancer","volume":"66","author":"Pulya","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114470","article-title":"Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer","volume":"238","author":"Pulya","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0125","article-title":"Design and synthesis of pyridine-based benzamides as potent HDAC3 inhibitors as an armament against breast cancer with in vivo validation","volume":"291","author":"Himaja","year":"2025","journal-title":"E. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0130","doi-asserted-by":"crossref","first-page":"8311","DOI":"10.1002\/slct.202001880","article-title":"Synthesis and anticancer research of n-(2-aminophenyl)benzamide acridine derivatives as dual topoisomerase i and isoform-selective HDAC inhibitors","volume":"5","author":"Zhang","year":"2020","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.109877_bb0135","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.3390\/ijms22115516","article-title":"8a, a new acridine antiproliferative and pro-apoptotic agent targeting HDAC1\/DNMT1","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109877_bb0140","doi-asserted-by":"crossref","first-page":"2206581","DOI":"10.1080\/14756366.2023.2206581","article-title":"Discovery of novel polysubstituted n-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy","volume":"38","author":"Wang","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0145","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1021\/acs.jmedchem.7b01404","article-title":"(N-Hydroxycarbonylbenylamino)quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo","volume":"61","author":"Lee","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0150","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1016\/j.bmc.2004.06.020","article-title":"Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities","volume":"12","author":"Maeda","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109877_bb0155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/adsc.200700328","article-title":"Auto-tandem catalysis: synthesis of substituted 11H-Indolo[3,2-c]quinolines via palladium-catalyzed intermolecular C-N and intramolecular C-C bond formation","volume":"350","author":"Meyers","year":"2008","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.bioorg.2026.109877_bb0160","doi-asserted-by":"crossref","first-page":"11262","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class i HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109877_bb0165","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mc.23214","article-title":"Role of class i histone deacetylases in the regulation of maspin expression in prostate cancer","volume":"59","author":"Shankar","year":"2020","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2026.109877_bb0170","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109877_bb0175","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-019-1752-8","article-title":"Activity of caspase-8 determines plasticity between cell death pathways","volume":"575","author":"Newton","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109877_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121193","article-title":"Constructing nanocomplexes by multicomponent self-assembly for curing orthotopic glioblastoma with synergistic chemo-photothermal therapy","volume":"279","author":"Lu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioorg.2026.109877_bb0185","doi-asserted-by":"crossref","first-page":"6369","DOI":"10.7314\/APJCP.2012.13.12.6369","article-title":"Vitexicarpin induces apoptosis in human prostate carcinoma PC-3 cells through G2\/M phase arrest","volume":"13","author":"Meng","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.bioorg.2026.109877_bb0190","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2008.243","article-title":"Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells","volume":"22","author":"Nishioka","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2026.109877_bb0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41389-021-00331-0","article-title":"A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo","volume":"10","author":"Wu","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bioorg.2026.109877_bb0200","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 k","volume":"105","author":"Mark","year":"2001","journal-title":"J. Phys. Chem. A"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600413X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600413X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:41:03Z","timestamp":1777452063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600413X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S004520682600413X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109877","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of novel N-arylamide-quinoline derivatives as HDAC isoform-selective inhibitors: in vitro and in vivo anticancer efficacy and pharmacokinetic studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109877"}}